Table 4.

Association of APOE Genotypes With ARIA Stratified by Symptomatic ARIA^a,b

ARIA-E
APOE genotype	Symptomatic (N = 125 vs 1,114 controls)				Asymptomatic (N = 382 vs 1,114 controls)				Symptomatic vs asymptomatic (N = 125 vs 382)
	OR	95% CI	RR	p Value	OR	95% CI	RR	p Value	OR	95% CI	RR	p Value
ε3/ε4	1.79	1.04–3.06	1.59	0.03	1.70	1.24–2.35	1.53	0.001	1.10	0.6–2.03	1.09	0.75
ε4/ε4	3.64	1.97–6.73	2.56	3.8E-05	4.56	3.13–6.63	2.90	2.2E-15	0.79	0.41–1.54	0.82	0.49

ARIA-H microhemorrhage
APOE genotype	Symptomatic (N = 38, vs 1,306 controls)				Asymptomatic (N = 277 vs 1,306 controls)				Symptomatic vs asymptomatic (N = 38 vs 277)
	OR	95% CI	RR	p Value	OR	95% CI	RR	p Value	OR	95% CI	RR	p Value
ε3/ε4	1.03	0.37–2.88	1.02	0.96	1.50	1.04–2.16	1.38	0.03	0.58	0.19–1.74	0.62	0.33
ε4/ε4	7.41	2.73–20.08	3.55	8.3E-05	4.20	2.76–6.37	2.72	1.7E-11	1.44	0.5–4.11	1.34	0.50

ARIA-H with superficial siderosis
APOE genotype	Symptomatic (N = 32 vs 1,400 controls)				Asymptomatic (N = 189 vs 1,400 controls)				Symptomatic vs asymptomatic (N = 32 vs 189)
	OR	95% CI	RR	p Value	OR	95% CI	RR	p Value	OR	95% CI	RR	p Value
ε3/ε4	4.81	1.08–21.35	3.48	0.04	3.01	1.81–5.00	2.51	2.1E-05	2.16	0.43–11.00	1.94	0.35
ε4/ε4	9.52	2.03–44.61	5.14	0.004	7.94	4.59–13.73	4.69	1.2E-13	1.27	0.24–6.77	1.24	0.78

^aValues are compared with the ε3/ε3 reference group.

^bModels controlled for age at study baseline, sex, study (ENGAGE or EMERGE), last dose level before the ARIA event or censor, and genetic ancestry measured by PCs 1–10. Ε2/ε3 and ε2/ε4 genotypes were excluded from these analyses because small sample sizes in these groups led to potential model convergence issues.